Orphenadrine citrate and Tecfidera drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Orphenadrine citrate and Tecfidera. Common interactions include pruritus among females.

The phase IV clinical study analyzes what interactions people who take Orphenadrine citrate and Tecfidera have. It is created by eHealthMe based on reports of 8 people who take Orphenadrine citrate and Tecfidera from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

With medical big data and AI algorithms, eHealthMe enables everyone to run phase IV clinical trial to detect adverse drug outcomes and monitor effectiveness. Our original studies have been referenced on 600+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Most recently, phase IV clinial trails for COVID 19 vaccines have been added, check here.



On May, 22, 2022

8 people who take Orphenadrine citrate and Tecfidera together, and have interactions are studied.


What is Orphenadrine citrate?

Orphenadrine citrate has active ingredients of orphenadrine citrate. It is often used in muscle aches. eHealthMe is studying from 934 Orphenadrine citrate users for its effectiveness, alternative drugs and more.

What is Tecfidera?

Tecfidera has active ingredients of dimethyl fumarate. It is often used in multiple sclerosis. eHealthMe is studying from 116,549 Tecfidera users for its effectiveness, alternative drugs and more.

Number of Orphenadrine citrate and Tecfidera reports submitted per year:

Orphenadrine citrate and Tecfidera drug interactions.

Common Orphenadrine Citrate and Tecfidera drug interactions by gender *:

female:

  1. Pruritus
  2. Asthenia
  3. Deafness
  4. Drug intolerance
  5. Fatigue
  6. Mobility decreased
  7. Pain
  8. Somnolence
  9. Stress
  10. Urticaria

male:

n/a

Common Orphenadrine Citrate and Tecfidera drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

  1. Erythema
  2. Loss of bladder sensation
  3. Loss of consciousness
  4. Memory impairment
  5. Pruritus

30-39:

n/a

40-49:

  1. Arthralgia
  2. Ataxia
  3. Confusional state
  4. Dementia
  5. Drug ineffective
  6. Dyspnoea exertional
  7. Eye pain
  8. Migraine without aura
  9. Mood disorder due to a general medical condition
  10. Pain in extremity

50-59:

  1. Abdominal discomfort
  2. Flushing
  3. Mobility decreased
  4. Pain
  5. Pruritus
  6. Stress
  7. Urticaria

60+:

n/a

* Approximation only. Some reports may have incomplete information.

Do you take Orphenadrine citrate and Tecfidera?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Browse all drug interactions of Orphenadrine citrate and Tecfidera:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Orphenadrine citrate interactions:

Browse all interactions between Orphenadrine citrate and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Tecfidera interactions:

Browse all interactions between Tecfidera and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on orphenadrine citrate and dimethyl fumarate (the active ingredients of Orphenadrine citrate and Tecfidera, respectively), and Orphenadrine citrate and Tecfidera (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: